GLRA
ALXN

Gerald L. Ray & Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Gerald L. Ray & Associates’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,500
Closed -$306K – 321
2016
Q4 		$306K Buy
+2,500
New +$306K 0.04% 255

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Gerald L. Ray & Associates's ALXN Position: Q1 2017 in Review

Gerald L. Ray & Associates sold out of Alexion Pharmaceuticals (ALXN) in Q1 2017, closing a stake of 2,500 shares — an estimated $306K sold.

Gerald L. Ray & Associates first reported a position in ALXN in Q4 2016 and held it in 1 quarter. The position peaked at $306K in Q4 2016. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

  • Gerald L. Ray & Associates reported no remaining Alexion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Gerald L. Ray & Associates sold 2,500 Alexion Pharmaceuticals shares in Q1 2017, an estimated $306K.
  • Gerald L. Ray & Associates first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Gerald L. Ray & Associates's Alexion Pharmaceuticals position peaked at $306K in Q4 2016.
  • 561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on Gerald L. Ray & Associates's 13F filing for Q1 2017, filed 3 May 2017.